Document is current
Any future updates will be listed below
-
Authors
Soliman, Sameh S. M. https://orcid.org/0000-0002-7691-615X
Baldin, Clara
Gu, Yiyou
Singh, Shakti https://orcid.org/0000-0001-6521-0998
Gebremariam, Teclegiorgis https://orcid.org/0000-0002-2295-058X
Swidergall, Marc https://orcid.org/0000-0002-5261-6267
Alqarihi, Abdullah https://orcid.org/0000-0003-4408-6398
Youssef, Eman G. https://orcid.org/0000-0002-3167-1347
Alkhazraji, Sondus
Pikoulas, Antonis
Perske, Christina
Venkataramani, Vivek
Rich, Abigail https://orcid.org/0000-0002-7301-1945
Bruno, Vincent M.
Hotopp, Julie Dunning https://orcid.org/0000-0003-3862-986X
Mantis, Nicolas J. https://orcid.org/0000-0002-5083-8640
Edwards, John E. Jr
Filler, Scott G. https://orcid.org/0000-0001-7278-3700
Chamilos, Georgios
Vitetta, Ellen S.
Ibrahim, Ashraf S. https://orcid.org/0000-0003-3787-8530
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R00DE026856, R01A11752861, R01AI063503, R01AI141360)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U19AI110820, R01AI141360, R01AI124566, R01DE022600)
- License Information
-
More Information
Article History
Received: 27 January 2020
Accepted: 20 November 2020
First Online: 18 January 2021
Competing interests
: A.S.I. owns shares in Vitalex Biosciences, a start-up company that is developing immunotherapies and diagnostics for mucormycosis. The Lundquist Institute has filed intellectual property rights concerning mucoricin (US patent application no. 16/462,511). Vitalex Biosciences has an option to license the technology from The Lundquist Institute for Biomedical Innovation. The remaining authors declare no competing interests.
